Clinical Trial Update: Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 and Temsirolimus in Treating Patients With Advanced Solid Tumors [Phase 1]

View source ↗

Summary

Phase 1 trial of RO4929097, a gamma-secretase/Notch pathway inhibitor, in combination with temsirolimus for advanced solid tumors has completed, including cohor…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Endometrial Cancer
• Renal Cell Carcinoma

Drugs mentioned

• RO4929097 (RO4929097)
• Temsirolimus (temsirolimus)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Endometrial Papillary Serous Carcinoma, Recurrent Endometrial Carcinoma | Phase 1 | Status: COMPLETED